Organization
FutureGen Biopharmaceutical (Beijing) Co, Beijing, Beijing, China
1 abstract
Abstract
Safety and efficacy results from the phase I/IIa study of FG-M108 plus CAPOX as first-line (1L) treatment for patients with CLDN18.2+/HER2- locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.Org: FutureGen Biopharmaceutical (Beijing) Co, Beijing, Beijing, China, Futuregen Biopharmaceutical (Beijing) Co., Ltd, Beijing, China, FutureGen Biopharmaceutical (Beijing) Co., Beijing, China,